A population based case-control study of cataract and inhaled corticosteroids

L Smeeth, M Boulis, R Hubbard, A E Fletcher

Background/aims: Exposure to systemic corticosteroid use is known to be associated with a risk of cataract. Whether low doses of inhaled corticosteroids are associated with an increased risk of cataract is not known. This study was undertaken to quantify the risk of cataract associated with the use of inhaled corticosteroids and assess whether there is a dose-response relation.

Methods: A population based case-control study based on the General Practice Research Database in the United Kingdom. 15 479 people with cataract and 15 479 controls were matched for age, sex, practice, and observation period.

Results: The crude odds ratio for the association between any recorded exposure to inhaled corticosteroids and cataract was 1.58 (95% CI 1.46 to 1.71), reduced to 1.10 (95% CI 1.00 to 1.20) after adjustment for systemic corticosteroid exposure and consultation rate. There was a dose-response relation, the adjusted odds ratio rising from 0.99 (95% CI 0.87 to 1.13) at daily doses up to 400 µg to 1.69 (95% CI 1.17 to 2.43) for daily doses greater than 1600 µg. The association was also stronger with increasing duration of use.

Conclusion: Higher doses and longer duration of exposure to inhaled corticosteroids are associated with an increased risk of cataract. The lowest doses compatible with good control of airways disease should be used. The risk of cataract associated with high doses of inhaled corticosteroids needs to be more widely appreciated.
Data processing and analysis

Data from the electronic records were extracted and set up as a relational database. Only drug exposure before the index date was included in the analyses.

Inhaled corticosteroid exposure was initially defined as ever or never. Exposure was further categorised as current (participants with at least one prescription within 180 days of the index date) and past (participants with prescriptions greater than 180 days before the index date, but with no recent prescriptions). The mean daily dose of inhaled corticosteroids was categorised as low (up to 400 mg/day), moderate (401–800 mg/day), high (801–1600 mg/day), and very high (greater than 1600 mg/day). In addition, the total number of prescriptions for inhaled corticosteroids was assessed. Information about exposure to all other corticosteroids was also extracted, divided into systemic oral, systemic parenteral, ocular, skin, nasal, ear, and other topical (including rectal, vaginal, intra-articular, and intracutaneous). Diagnoses of asthma and chronic obstructive pulmonary disease (COPD) were extracted for descriptive purposes. Data on the following potential confounding factors were extracted: smoking habit; body mass index (weight in kilograms divided by the square of height in metres); diabetes mellitus; and glaucoma. Because frequency of consultation with the general practitioner could affect both the likelihood of a diagnosis of cataract and be associated with drug exposures, consultation rate was considered as a potential confounding factor. The mean annual consultation rate for each participant was calculated, defined as the total number of consultations divided by the years of observation period.

Following the initial descriptive analysis, exposure to inhaled corticosteroids and to all other types of corticosteroids was modelled as a binary ever/never exposures using conditional logistic regression. We then fitted a series of bivariate models, retaining variables that led to a change in the odds ratio for inhaled corticosteroids by 10% or more. The primary analysis determined the relation between the use of inhaled corticosteroids and the incidence of cataract. We then assessed the effects of different daily doses of and total number of prescriptions for inhaled corticosteroids.

Study power

Based on a previous study using the same database, we estimated that the prevalence of inhaled steroid use among controls was likely to be at least 5%. The study had over 90% power at the 5% significance level to detect a minimum relative risk of cataract associated with use of inhaled corticosteroids of 1.25.

RESULTS

A total of 15 588 people with a diagnosis of cataract were sampled. People with diagnoses of congenital or traumatic cataract were excluded (109 cases), leaving 15 479 case-control...
pairs. Descriptive details of cases and controls are shown in Table 1. The mean age of participants was 75.0 years and 64.6% were female. The mean observation period before the index date was 4.5 years. Cases consulted their general practitioners considerably more often than controls, reflected in the higher mean annual consultation rate. In the crude analyses, both COPD and asthma were associated with an increased risk of cataract.

Table 2 shows the numbers of cases and controls ever exposed to different corticosteroids and the univariate associations between corticosteroid exposure and cataract. The proportions of cases and controls exposed to an inhaled corticosteroid were 11.4% and 7.6% respectively. The crude odds ratio for the association between any recorded exposure to inhaled corticosteroids and cataract was 1.58 (95% CI 1.46 to 1.71). In univariate analyses, recorded exposure to any type of corticosteroid was associated with a diagnosis of cataract.

The association between inhaled corticosteroids and cataract was reduced when adjusted for systemic corticosteroid exposure and mean annual consultation rate (Table 3). The association was not further affected by adjustment for systemic corticosteroid, 77% were exposed to beclomethasone only, the adjusted odds ratios show that recorded exposure to beclomethasone was associated with a small non-significant increased risk of cataract. Although the odds ratios for the association between exposure to the different inhaled corticosteroids, systemic corticosteroids, and for consultation rate wholly explained the association between diagnosed COPD and cataract and between diagnosed asthma and cataract. The adjusted odds ratio for the association between COPD and cataract was 1.03 (95% CI 0.94 to 1.13) compared with a crude odds ratio of 1.49 (see Table 1). The adjusted odds ratio for asthma and cataract was 1.05 (95% CI 0.95 to 1.16) compared with a crude odds ratio of 1.52 (see Table 1).

The numbers of people exposed to individual inhaled corticosteroids are shown in Table 4. The large majority of people exposed to any inhaled corticosteroid were exposed to beclomethasone only. Of cases exposed to inhaled corticosteroid, 77% were exposed to beclomethasone only, the corresponding figure for controls was 79.5%. The numbers of people receiving prescriptions for budesonide or fluticasone were low, as were the numbers of participants with prescriptions recorded for more than one type of inhaled corticosteroid. The adjusted odds ratios show that recorded exposure to beclomethasone was associated with a small non-significant increased risk of cataract. Although the odds ratios for the association between exposure to the different inhaled corticosteroids were all before 180 days before the index date (Table 3). There was evidence for a dose-response relation, the adjusted odds ratio rising from 0.99 (95% CI 0.87 to 1.13) at daily doses up to 400 µg to 1.69 (95% CI 1.17 to 2.43) for daily doses greater than 1600 µg, p = 0.004 for trend. Controlling for exposure to inhaled corticosteroids, systemic corticosteroids, and for consultation rate wholly explained the association between diagnosed COPD and cataract and between diagnosed asthma and cataract. The adjusted odds ratio for the association between COPD and cataract was 1.03 (95% CI 0.94 to 1.13) compared with a crude odds ratio of 1.49 (see Table 1). The adjusted odds ratio for asthma and cataract was 1.05 (95% CI 0.95 to 1.16) compared with a crude odds ratio of 1.52 (see Table 1).

The numbers of people exposed to individual inhaled corticosteroids are shown in Table 4. The large majority of people exposed to any inhaled corticosteroid were exposed to beclomethasone only. Of cases exposed to inhaled corticosteroid, 77% were exposed to beclomethasone only, the corresponding figure for controls was 79.5%. The numbers of people receiving prescriptions for budesonide or fluticasone were low, as were the numbers of participants with prescriptions recorded for more than one type of inhaled corticosteroid. The adjusted odds ratios show that recorded exposure to beclomethasone was associated with a small non-significant increased risk of cataract. Although the odds ratios for the association between exposure to the different inhaled corticosteroids were all before 180 days before the index date (Table 3). There was evidence for a dose-response relation, the adjusted odds ratio rising from 0.99 (95% CI 0.87 to 1.13) at daily doses up to 400 µg to 1.69 (95% CI 1.17 to 2.43) for daily doses greater than 1600 µg, p = 0.004 for trend. Controlling for exposure to inhaled corticosteroids, systemic corticosteroids, and for consultation rate wholly explained the association between diagnosed COPD and cataract and between diagnosed asthma and cataract. The adjusted odds ratio for the association between COPD and cataract was 1.03 (95% CI 0.94 to 1.13) compared with a crude odds ratio of 1.49 (see Table 1). The adjusted odds ratio for asthma and cataract was 1.05 (95% CI 0.95 to 1.16) compared with a crude odds ratio of 1.52 (see Table 1).

Table 3  Association between exposure to inhaled corticosteroids and cataract: adjusted models and dose-response relation

<table>
<thead>
<tr>
<th>Inhaled corticosteroids:</th>
<th>Cases (n = 15479)</th>
<th>Controls (n = 15479)</th>
<th>Univariate analysis</th>
<th>Adjusting for systemic steroids</th>
<th>Adjusting for systemic steroids and consultation rate</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Odds ratio (95% CI)</td>
<td>Odds ratio (95% CI)</td>
<td>Odds ratio (95% CI)</td>
<td>Odds ratio (95% CI)</td>
<td>p Value</td>
</tr>
<tr>
<td>Never</td>
<td>13713 (88.6%)</td>
<td>14299 (92.4%)</td>
<td>Baseline</td>
<td>Baseline</td>
<td>Baseline</td>
</tr>
<tr>
<td>Ever</td>
<td>1766 (11.4%)</td>
<td>1180 (7.6%)</td>
<td>1.58 (1.46 to 1.71)</td>
<td>1.32 (1.21 to 1.44)</td>
<td>1.10 (1.00 to 1.20)</td>
</tr>
<tr>
<td>Current</td>
<td>1319 (8.5%)</td>
<td>829 (5.4%)</td>
<td>1.67 (1.53 to 1.83)</td>
<td>1.39 (1.26 to 1.53)</td>
<td>1.15 (1.03 to 1.27)</td>
</tr>
<tr>
<td>Past only</td>
<td>447 (2.9%)</td>
<td>351 (2.3%)</td>
<td>1.35 (1.17 to 1.56)</td>
<td>1.16 (1.00 to 1.35)</td>
<td>0.98 (0.84 to 1.14)</td>
</tr>
<tr>
<td>Daily dose:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>None</td>
<td>13713 (88.6%)</td>
<td>14299 (92.4%)</td>
<td>Baseline</td>
<td>Baseline</td>
<td>Baseline</td>
</tr>
<tr>
<td>Low (up to 400 µg)</td>
<td>6377 (4.1%)</td>
<td>496 (3.2%)</td>
<td>1.36 (1.20 to 1.53)</td>
<td>1.18 (1.05 to 1.34)</td>
<td>0.99 (0.87 to 1.13)</td>
</tr>
<tr>
<td>Moderate (401–800 µg)</td>
<td>430 (2.8%)</td>
<td>264 (1.7%)</td>
<td>1.73 (1.48 to 2.02)</td>
<td>1.45 (1.24 to 1.71)</td>
<td>1.18 (1.00 to 1.39)</td>
</tr>
<tr>
<td>High (801–1600 µg)</td>
<td>382 (2.5%)</td>
<td>221 (1.4%)</td>
<td>1.82 (1.54 to 2.15)</td>
<td>1.46 (1.23 to 1.74)</td>
<td>1.18 (0.99 to 1.42)</td>
</tr>
<tr>
<td>Very high (&gt;1600 µg)</td>
<td>117 (0.8%)</td>
<td>43 (0.3%)</td>
<td>2.87 (2.02 to 4.08)</td>
<td>2.21 (1.55 to 3.16)</td>
<td>1.69 (1.17 to 2.43)</td>
</tr>
<tr>
<td>Missing data</td>
<td>200 (1.3%)</td>
<td>156 (1.0%)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 4  Individual inhaled corticosteroids: recorded exposure and association with cataract

<table>
<thead>
<tr>
<th>Variable</th>
<th>Cases (n = 15479)</th>
<th>Controls (n = 15479)</th>
<th>Univariate odds ratio (95% CI)</th>
<th>Adjusted for systemic steroids and consultation rate</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Odds ratio (95% CI)</td>
<td>Odds ratio (95% CI)</td>
<td>p Value</td>
<td></td>
</tr>
<tr>
<td>No inhaled corticosteroid</td>
<td>13713 (88.59%)</td>
<td>14299 (92.38%)</td>
<td>Baseline</td>
<td></td>
</tr>
<tr>
<td>Beclomethasone only</td>
<td>1359 (8.78%)</td>
<td>938 (6.06%)</td>
<td>1.53 (1.40 to 1.67)</td>
<td>1.08 (0.98 to 1.19)</td>
</tr>
<tr>
<td>Budesonide only</td>
<td>181 (1.17%)</td>
<td>113 (0.73%)</td>
<td>1.69 (1.33 to 2.14)</td>
<td>1.16 (0.91 to 1.50)</td>
</tr>
<tr>
<td>Fluticasone only</td>
<td>23 (0.15%)</td>
<td>8 (0.05%)</td>
<td>3.02 (1.35 to 6.77)</td>
<td>1.96 (0.84 to 4.56)</td>
</tr>
<tr>
<td>Mixed</td>
<td>203 (1.31%)</td>
<td>121 (0.78%)</td>
<td>1.76 (1.40 to 2.21)</td>
<td>1.08 (0.85 to 1.37)</td>
</tr>
</tbody>
</table>

*p Value for trend.
types of inhaled corticosteroid and cataract were all positive, none were significant. The levels of exposure were too low to provide adequate power to assess the whether the effects of individual drugs differed.

DISCUSSION

The results of this study suggest that high doses of inhaled corticosteroids used for prolonged periods are associated with an increased risk of cataract formation. This finding is consistent with the known risk of cataract associated with systemic corticosteroids and the increasing recognition that inhaled corticosteroids, particularly at higher doses, can have systemic effects. For the relatively small proportion of people prescribed daily doses of 1600 μg or more, 41% of their risk of cataract could be attributed to their exposure to inhaled corticosteroids, assuming the association between exposure and cataract was causal. We have also shown that while people with a diagnosis of COPD or asthma have around a 50% increased risk of cataract, the increased risk can be attributed to previous exposure to inhaled and systemic corticosteroids.

Cases included in the study were people with a clinical diagnosis of cataract. It is likely therefore that some people with early cataracts would have been missed and could have been included in the control group. However, there is no reason to suspect this misclassification would be differential with regard to exposure status and thus while there may have been a small reduction in power, this misclassification is unlikely to have biased the effect estimate. A recent study demonstrated a high degree of validity (94%) for a recorded diagnosis of cataract in the GPRD. Clinical presentation will be determined largely by a number of factors—firstly, by the severity of the opacity, meaning that diagnosis is one way of assessing the stage of the disease. Cataract is not an all or nothing disease: there is a continuous spectrum of severity from blinding cataract to minor opacities that would only be found on detailed examination. Using clinical presentation as an indicator of severity is in line with modern epidemiological thinking about risk factors: assessing how much disease is present rather than whether there is any or none. The second factor likely to determine clinical diagnosis is frequency of clinic attendance. We were able to control for the confounding effect of consultation rate on the association between inhaled corticosteroids and diagnosed cataract. The third important factor determining the stage of clinical presentation relates to the healthcare provider. In this study cases and controls were matched on general practice (primary care clinic) reducing the chance of systematic differences in the ascertainment of cataract between the two comparison groups. We had no information about type of cataract. However, the large numbers of cases and the mixed population in this study mean we would have had a representative mix of different types of cataract. The important issues both for individuals and for public health involve the risks associated with having any type of cataract, not a specific subcategory. Cases were selected from the existing cohort of patients within the GPRD using simple random sampling so there was no potential for selection bias.

The levels of missing data for smoking and BMI were higher among controls than among cases. For both cases and controls, well over half the people with missing data were in the lowest category for consultation rate. This is as expected: people who attended the doctor less were less likely to have their smoking status and BMI recorded. Controls were more likely to be in the lowest category for consultation rate, and were therefore more likely to have missing data from smoking and BMI. The observed lack of association between cataract and current or ex-smoking is inconsistent with smoking being an established risk factor for the disease.

While the prevalence of current smoking is consistent with that recorded in a large representative household survey in the United Kingdom, the level of ex-smoking is much lower than would be expected. We have previously shown that for people recorded as being current smokers, the magnitude and direction of the dose-response relation with the risk of lung cancer are what would be expected, suggesting that a code for current smoking is accurate. A likely explanation for the observed lack of association between cataract and either current or ex-smoking when compared with non-smoking is that many people recorded as being non-smokers are in fact ex-smokers. It is possible that we failed to completely control for confounding by smoking in the association between inhaled corticosteroids and cataracts. However, when the analysis was restricted to smokers only, the association between any exposure to inhaled corticosteroids and cataracts was virtually identical to the result for all participants (adjusted odds ratio for all participants 1.10 and for smokers only 1.12). In addition, the dose-response relation between inhaled corticosteroid exposure and cataract remained and was similar to that seen for all participants. It is therefore unlikely that residual confounding by smoking explained the observed association between inhaled corticosteroid exposure and cataract.

Prescription data were recorded before the subject became a case so there was no potential for recall bias. Drug prescriptions from practices participating in the GPRD are generated by the practice computers ensuring the accuracy of the electronic prescribing records. We lacked information about drug exposures before participants registered with the General Practice Research Database and it is possible that we may not have been able to fully control for systemic corticosteroids prescribed in the years before data collection started. In addition, our estimate of exposure was based on drugs prescribed rather than drugs known to have been taken. While this may have led to a small degree of misclassification of exposure status, there is no reason to suspect this would be differential with regard to diagnosis and thus while there may have been a small reduction in power, any such misclassification is unlikely to have biased the effect estimate.

A previous smaller study using the GPRD has also assessed the risk of cataract associated with the use of inhaled corticosteroids. This study included only 1194 cases compared with the 15,479 included in our study, and was based on an earlier version of the GPRD. Importantly, this study did not control for the effects of consultation rate, demonstrated in our study to be an important confounder. Despite this, however, the results of this study, and two other major clinical studies, are consistent with our findings of an increased risk of cataract associated with inhaled corticosteroids.

High doses and prolonged use of inhaled corticosteroids are associated with an increased risk of cataract independent of exposure to other types of corticosteroid medications. This risk adds to the growing literature on the potential for adverse effects from the use of inhaled corticosteroids. These risks need to be considered in the light of the large beneficial effects value of inhaled corticosteroids to many patients with asthma and to some patients with chronic obstructive pulmonary disease. While lower doses have not been shown to be completely without risk, there is good evidence to suggest that lower doses are associated with a reduced risk of adverse effects. The risk of cataract associated with high doses of inhaled corticosteroids needs to be more widely recognised.

ACKNOWLEDGEMENTS

We would like to thank Chris Smith for help with data processing.
The study was funded by the Gift of Thomas Pocklington. Liam Smeeth is supported by an MRC clinical scientist fellowship. Richard Hubbard is supported by a Wellcome Trust advanced fellowship.

REFERENCES

A population based case-control study of cataract and inhaled corticosteroids

L Smeeth, M Boulis, R Hubbard and A E Fletcher

*Br J Ophthalmol* 2003 87: 1247-1251
doi: 10.1136/bjo.87.10.1247